The fusion of mRNA technology with AI has laid the foundation for ushering in a new era of cancer care. However, conducting ...

Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $428 million specializing in mRNA therapeutics and vaccines, stands at a ...

The latest guidance reduction was the second time in the last six months that the firm has revised its forecast in a negative ...

A Massachusetts biopharma giant is at the center of preparations already underway if bird flu mutates and begins to find ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

We recently compiled a list of the 12 Best S&P 500 Stocks to Invest in According to Analysts. In this article, we are going ...

But that doesn’t mean an H5N1 avian influenza pandemic isn’t possible ... million to help accelerate the development of a bird flu vaccine. The agency announced its backing of the ...

The research evaluates the vaccine's immunogenicity and protective efficacy in both murine and avian models, seeking to establish a new paradigm for avian influenza vaccination strategies. The mRNA ...

The US Department of HHS is awarding the pharmaceutical company Moderna $590 million to continue developing a vaccine to protect against bird flu.

GSK has upgraded its longstanding alliance with CureVac on mRNA-based vaccines for respiratory ... candidate also in phase 2 and one for avian influenza in phase 1. GSK said that the data so ...